Tateishi 2011.

Methods	Participants were not receiving any lipid‐altering agents; no wash‐out period was required 12‐Week randomised trial
Participants	78 men and women with hypercholesterolaemia; LDL‐C ≥ 140 mg/dL (3.62 mmol/L) 26 participants received atorvastatin, 26 received rosuvastatin, 26 received pitavastatin Exclusion criteria: participants receiving statins Atorvastatin 10 mg/d baseline LDL‐C: 4.30 mmol/L (166 mg/dL) Atorvastatin 10 mg/d baseline HDL‐C: 1.24 mmol/L (48 mg/dL) Atorvastatin 10 mg/d baseline TG: 1.735 mmol/L (154 mg/dL)
Interventions	Rosuvastatin 2.5 mg/d for 0 to 12 weeks Rosuvastatin 5 mg/d for 12 to 24 weeks Atorvastatin 10 mg/d Pitavastatin 2 mg/d
Outcomes	Per cent change from baseline at 12 weeks of serum LDL‐C, HDL‐C and triglycerides
Notes	Rosuvastatin 2.5 mg/d for 0 to 12 weeks Rosuvastatin 5 mg/d for 12 to 24 weeks Pitavastatin 2 mg/d Groups were not included in the efficacy analysis SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	High risk	Total cholesterol was not included in the efficacy analysis
Other bias	Unclear risk	The source of funding was not reported